Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market - Industry Trends and Forecast to 2030

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market - Industry Trends and Forecast to 2030

Asia-Pacific Chinese hamster ovary (CHO) cells market is projected to register a CAGR of 9.9% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation

Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market, Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Dynamics

Driver
• Rising use of CHO cells in the genetic study
Restraint
• High cost of CHO cell-based production
Opportunity
• Continuous development of cell culture technologies
Market Players
Some major companies dealing in the Asia-Pacific Chinese hamster ovary (CHO) cells market are:
• Thermo Fisher Scientific Inc. (U.S.)
• AcceGen (U.S.)
• RayBiotech Life, Inc. (U.S.)
• CLS Cell Lines Service GmbH (Germany)
• BPS Bioscience, Inc. (U.S.)
• GenTarget Inc. (U.S.)
• Merck KGaA (Germany)
• Promega Corporation (U.S.)
• Abeomics (U.S.)
• Applied Biological Materials Inc. (abm) (Canada)
• ATCC (U.S.)
• Sartorius AG (Germany)
• Lonza (Switzerland)
• Horizon Discovery Ltd. (U.K.)
• Cytiva (U.S.)
• Curia global, Inc. (U.S.)